In this podcast episode, McCall McPherson explores the complexities of Graves' disease and hypothyroidism
In 2025, the company reported a +4.31% YoY revenue growth, driven by its specialty segment momentum: Austedo ($2.21B) continues to be the key growth driver with strong uptake in movement disorders, Copaxone ($255M) continues its decline due to generic competition, while UZEDY ($191M) is gaining early traction as a long-acting injectable for schizophrenia, reflecting Tevas push into differentiated CNS therapies
Painful and immobilizing joint conditions like osteoarthritis develop as a consequence of repeated stress on the joints
However, they are not miracle drugs
doi:10.1172/JCI78371 Zheng Z, Zong Y, Ma Y, et al
Protein should be the foundation of every meal